Compare IDT & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDT | KURA |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 1996 | N/A |
| Metric | IDT | KURA |
|---|---|---|
| Price | $51.40 | $10.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 168.5K | ★ 1.7M |
| Earning Date | 12-04-2025 | 11-04-2025 |
| Dividend Yield | ★ 0.46% | N/A |
| EPS Growth | ★ 10.35 | N/A |
| EPS | ★ 3.22 | N/A |
| Revenue | ★ $1,244,681,000.00 | $104,029,000.00 |
| Revenue This Year | $0.77 | $138.16 |
| Revenue Next Year | N/A | $67.37 |
| P/E Ratio | $16.19 | ★ N/A |
| Revenue Growth | ★ 2.52 | N/A |
| 52 Week Low | $44.77 | $5.41 |
| 52 Week High | $71.12 | $12.49 |
| Indicator | IDT | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 43.21 |
| Support Level | $47.30 | $10.17 |
| Resistance Level | $52.72 | $10.90 |
| Average True Range (ATR) | 1.80 | 0.58 |
| MACD | 0.30 | -0.23 |
| Stochastic Oscillator | 52.02 | 7.44 |
IDT Corp is a multinational holding company. It operates in the telecommunications and payment industries. It has four reportable business segments, Fintech, National Retail Solutions; net2phone and Traditional Communications, The Fintech segment is comprised of National Retail Solutions (NRS), an operator of a nationwide point of sale (POS) network providing payment processing, digital advertising, transaction data, and ancillary services, and BOSS Money, a provider of international money remittance and related value/payment transfer services. The net2phone segment provides unified cloud communications and telephony services to business customers.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.